B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR)

Highlights • Targeting the dimer interface of EGFR, a novel strategy for promoting the clinic response rate of anti-EGFR therapy was first suggested. • The peptide from the dimer interface of EGFR was immunogenic and able to elicit high titer anti-peptide antibodies (Abs) both in mouse and rabbit. • The peptide-specific Abs can recognize the native EGFR of A431 cell in vitro. • The peptide vaccine can inhibit the growth of transplantable tumor in vivo.